All In Biotech

NDA 215133 · Almatica

Sertraline Hydrochloride

Sertraline Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Oct 4, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

369

75 Phase 3, 32 recruiting

FAERS reports

39,393

27,842 serious, 4,133 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 )

What it is approved for

From the label in effect Oct 2, 2026.

Sertraline Hydrochloride (HCl) Capsules is indicated for the treatment of the following [see Clinical Studies ( 14 )] : Major depressive disorder (MDD) in adults Obsessive-compulsive disorder (OCD) in adults and pediatric patients 6 years and older Sertraline Hydrochloride (HCl) Capsules is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of ( 1 ): Major depressive disorder (MDD) in adults Obsessive-compulsive disorder (OCD) in adults and pediatric patients 6 years and older

Mechanism: Sertraline potentiates serotonergic activity in the central nervous system through inhibition of neuronal reuptake of serotonin (5-HT).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 4, 2021 Original approval · Type 3 - New Dosage Form LabelLetterReview
  • Oct 4, 2021 Original approval · Type 3 - New Dosage Form LetterReview
2 products under this application
  • SERTRALINE HYDROCHLORIDE · SERTRALINE HYDROCHLORIDE EQ 150MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • SERTRALINE HYDROCHLORIDE · SERTRALINE HYDROCHLORIDE EQ 200MG BASE · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sertraline" as an intervention, any sponsor and status, largest first.

All 369 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,045
  • nausea2,693
  • headache2,471
  • fatigue2,343
  • depression2,043
  • diarrhoea1,972
  • anxiety1,942
  • dizziness1,838
  • drug interaction1,779
  • dyspnoea1,743
  • off label use1,633
  • vomiting1,525

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004649
2005737
2006156
2007208
2008274
2009961
20101,788
20112,133
20122,234
2013950
20141,080
20151,601
20161,759
20171,946
20182,186
20192,655
20202,670
20212,466
20222,762
20232,281
20242,555
20252,878
20262,464

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,445 on PubMed

Sponsor: Almatica

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.